Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

Abstract

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia Luciana Machado, Ivete Alonso Bredda Saad, Helen Naemi Honma, André Moreno Morcillo, Lair Zambon Abstract Objective: To evaluate the effect of chemotherapy on the physical condition of patients with advanced lung cancer. Methods: We evaluated 50 patients with non-small cell lung cancer (in stages IIIB and IV) and Eastern Cooperative Oncology Group (ECOG) performance status scale scores between zero and two. All patients underwent chemotherapy using paclitaxel and platinum derivatives and were evaluated at three time points (prechemotherapy, postchemotherapy and six months after starting the treatment), at which the ECOG scale, the body mass index (BMI) and the six-minute walk distance (6MWD) were assessed. Results: Of the 50 patients included in the study, 14 died, 5 were excluded due to the worsening of their performance status, and 31 completed the six-month follow-up. There was no statistically significant difference between the time points of assessment for BMI (prechemotherapy vs. postchemotherapy, p = 1.00; and prechemotherapy vs. six months later, p = 0.218) or for 6MWD. Performance status improved, and this was especially due to the increase in the number of asymptomatic patients after the six-month follow-up (p = 0.031). Conclusions: Chemotherapy had a beneficial effect on the performance status of the patients. No significant changes in BMI or 6MWD were found during the study period, which might suggest the maintenance of the physical condition of the patients. 2 ) and carboplatin (area under the curve/5 = 300-600 mg/m 2 ). The initial exclusion criteria were as follows: having previously undergone lung surgery; and presenting with brain metastasis. During the study period, patients who presented with an ECOG PS score > 2 were excluded, in accordance with the treatment protocol of our facility, where chemotherapy is not given to such patients. (7) Therefore, the only exclusion criterion adopted during the follow-up visits was presenting with an elevated ECOG PS scale score (> 2).All of the patients gave written informed consent. The study was approved by the local research ethics committee (ruling no. 209/2006).The patients were selected during medical visits to the Lung Cancer Outpatient Clinic of the State University at Campinas Hospital das Clínicas, located in the city of Campinas, Brazil.After the inclusion criteria had been applied, the patients were evaluated and data were collected.The evaluations and data collection were carried out at three time points: prechemotherapy; postchemotherapy (two weeks after the last cycle of chemotherapy); and six months after the start of treatment. The evaluation consisted of collecting personal data, determining PS, evaluating BMI, and administering the 6MWT.In order to determine the PS, we used the ECOG scale, which measures the overall functional performance of patients...

A survey of recently published cardiovascular, hematological and pneumological original articles in the Brazilian scientific press

“…Machado et al94 evaluated the effect of chemotherapy on the physical condition of patients with advanced lung cancer and observed a beneficial effect on the performance status of the patients. No significant changes in BMI or 6MWD were found during the study period, which might suggest the maintenance of the physical condition of the patients.…”

Avaliação da qualidade de vida e função pulmonar em pacientes com câncer de pulmão

“…O perfil epidemiológico dos pacientes com câncer de pulmão em nosso estudo coincide com trabalhos prévios, com predominância das seguintes características: sexo masculino, faixa etária média acima de 60 anos, fumantes [15][16][17] , tipo histológico adenocarcinoma, e estadiamento IIIB e IV nos casos de CPNPC [16][17][18][19] epidermoide, mas ambos estão relacionados ao tabagismo 20,21 . Os sintomas pré-tratamento mais frequentemente relatados pelos nossos pacientes foram os respiratórios.…”

“…Esse achado está de acordo com estudo prévio, no qual não se identificou piora significativa no TC6' após o término da quimioterapia e nem seis meses após seu início em pacientes com câncer de pulmão (estágio IIIB e IV) 15 . No presente estudo, não houve diferença ao se analisar os parâmetros da função pulmonar em pacientes cirúrgicos nos três momentos.…”

The Role of Nutritional Support in Malnourished Patients With Lung Cancer

“…On diagnosis of lung cancer, the proportion of patients with low body weight is usually low (3-7.5%), while in the case of patients with excessive body weight, it is about 37-49% (36)(37)(38). Body weight loss prior to treatment is observed in about 58% of patients with NSCLC, 59% of patients with small cell lung cancer, and 76% of patients with pleural mesothelioma (39), and usually increases over the course of chemotherapy.…”